| Recruitment status | Preinitiation |
| Unique ID issued by UMIN | UMIN000033832 |
| Receipt No. | R000038587 |
| Official scientific title of the study | Investigation of promoting osteogenesis by intake of vitamin K2-rich Natto |
| Date of disclosure of the study information | 2018/08/21 |
| Last modified on | 2018/08/21 (Ver. 1) |
| Basic information | ||
| Official scientific title of the study | Investigation of promoting osteogenesis by intake of vitamin K2-rich Natto | |
| Title of the study (Brief title) | Investigation of promoting osteogenesis by intake of vitamin K2-rich Natto | |
| Region |
|
|
| Condition | ||
| Condition | Healthy Adult | |
| Classification by specialty |
|
|
| Classification by malignancy | Others | |
| Genomic information | NO | |
| Objectives | |
| Narrative objectives1 | Promoting osteogenesis and improving bone metabolism function when feeding Natto for 6 weeks
|
| Basic objectives2 | Efficacy |
| Basic objectives -Others | |
| Trial characteristics_1 | |
| Trial characteristics_2 | |
| Developmental phase | |
| Assessment | |
| Primary outcomes | Blood (osteocalcin) |
| Key secondary outcomes | Urine (Type I collagen cross-linked N- telopeptide),
Urine (deoxypyridinoline), Blood (vitamin K2) |
| Base | |
| Study type | Interventional |
| Study design | |
| Basic design | Single arm |
| Randomization | Non-randomized |
| Randomization unit | |
| Blinding | Open -no one is blinded |
| Control | Uncontrolled |
| Stratification | |
| Dynamic allocation | |
| Institution consideration | |
| Blocking | |
| Concealment | |
| Intervention | ||
| No. of arms | 1 | |
| Purpose of intervention | Treatment | |
| Type of intervention |
|
|
| Interventions/Control_1 | Natto | |
| Interventions/Control_2 | ||
| Interventions/Control_3 | ||
| Interventions/Control_4 | ||
| Interventions/Control_5 | ||
| Interventions/Control_6 | ||
| Interventions/Control_7 | ||
| Interventions/Control_8 | ||
| Interventions/Control_9 | ||
| Interventions/Control_10 | ||
| Eligibility | ||||
| Age-lower limit |
|
|||
| Age-upper limit |
|
|||
| Gender | Female | |||
| Key inclusion criteria | Postmenopausal women of ages 40 to 64 years old | |||
| Key exclusion criteria | 1. Persons who has liver disease, renal disease, digestive organ disease, heart trouble, peripheral vascular disorder, a person with a history of the past that may have an influence on other final examination results or person with a history of the operation
2. Person who take warfarin 3. Persons who liver function and renal function test values show abnormalities 4. Currently, those with a disorder under treatment 5. Persons who have food or drug allergy 6. Person who suffer from anemia 7. Persons who do intense sports or are on a diet 8. Persons who can't stop using functional foods (including Food for Specified Health Uses or Foods with Function Claims) and/or Specified quasi-drugs during the current study periods 9. Persons who are taking healthfoods, quasi medical items, medicines (including OTC, prescription medicine) containing ingredients contained in the test food 10. Persons who consume excess alcohol or can not abstinence from the day before the test until the day 11. Persons who are pregnant, or persons who are planning to become pregnant or breastfeeding during the study period 12. Persons who are participating in the other study or planning to participate during the study period 13. Persons who judged inappropriate by the study responsible doctor for other reasons |
|||
| Target sample size | 15 | |||
| Research contact person | |
| Name of lead principal investigator | Naoki Miura |
| Organization | Miura Clinic, Medical Corporation Kanonkai |
| Division name | Internal Medicine |
| Address | 9F Higashitenma Bldg.,1-7-17 Higashitenma, Kita-ku, Osaka-shi, Osaka, Japan |
| TEL | 06-6135-5200 |
| info@miura-cl.jp | |
| Public contact | |
| Name of contact person | Makoto Terashima |
| Organization | Oneness Support Co., Ltd. |
| Division name | Clinical trial Division |
| Address | 9F Higashitenma Bldg.,1-7-17 Higashitenma, Kita-ku, Osaka-shi, Osaka, Japan |
| TEL | 06-4801-8917 |
| Homepage URL | |
| mterashima@miura-cl.jp | |
| Sponsor | |
| Institute | Takanofoods Co., Ltd. |
| Institute | |
| Department | |
| Funding Source | |
| Organization | Takanofoods Co., Ltd. |
| Organization | |
| Division | |
| Category of Funding Organization | Profit organization |
| Nationality of Funding Organization | |
| Other related organizations | |
| Co-sponsor | Miura Clinic, Medical Corporation Kanonkai
Oneness Support Co., Ltd. |
| Name of secondary funder(s) | |
| Secondary IDs | |
| Secondary IDs | NO |
| Study ID_1 | |
| Org. issuing International ID_1 | |
| Study ID_2 | |
| Org. issuing International ID_2 | |
| IND to MHLW | |
| Institutions | |
| Institutions | |
| Other administrative information | |||||||
| Date of disclosure of the study information |
|
||||||
| Progress | |||||||
| Recruitment status | Preinitiation | ||||||
| Date of protocol fixation |
|
||||||
| Anticipated trial start date |
|
||||||
| Last follow-up date | |||||||
| Date of closure to data entry | |||||||
| Date trial data considered complete | |||||||
| Date analysis concluded | |||||||
| Related information | |
| URL releasing protocol | |
| Publication of results | Unpublished |
| URL releasing results | |
| Results | |
| Other related information | |
| Management information | |||||||
| Registered date |
|
||||||
| Last modified on |
|
||||||
| Link to view the page | |
| URL(English) | https://upload.umin.ac.jp/cgi-open-bin/ctr_e/ctr_view.cgi?recptno=R000038587 |